Neurologists have observed for decades that Lewy bodies, clumps of aggregated proteins inside cells, appear in the brains of patients with Parkinson's disease and other neurodegenerative diseases.
The presence of Lewy bodies suggests underlying problems in protein recycling and waste disposal, leading to the puzzle: how does disrupting those processes kill brain cells?
One possible answer: by breaking a survival circuit called MEF2D. Researchers at Emory University School of Medicine have discovered that MEF2D is sensitive to the main component of Lewy bodies, a protein called alpha-synuclein.
In cell cultures and animal models of Parkinson's, an accumulation of alpha-synuclein interferes with the cell's recycling of MEF2D, leading to cell death. MEF2D is especially abundant in the brains of people with Parkinson's, the researchers found.
The results are scheduled for publication in the Jan. 2, 2009 issue of Science.
"We've identified what could be an important pathway for controlling cell loss and survival in Parkinson's disease," says senior author Zixu Mao, PhD, associate professor of pharmacology at Emory University School of Medicine.
Further research could identify drugs that could regulate MEF2D, allowing brain cells to survive toxic stresses that impair protein recycling, he suggests.
Most cases of Parkinson's disease are termed sporadic, meaning that there is no obvious genetic cause, but there are inherited forms of Parkinson's. Some of these can be linked to mutations in the gene for alpha-synuclein or triplications of the gene. The mutations and triplications cause the brain to produce either a toxic form of alpha-synuclein or more alpha-synuclein than normal.
"Somehow it's toxic, but alpha-synuclein isn't part of the cell's machinery of death and survival," Mao says.
He and his colleagues began examining how alpha-synuclein influenced MEF2D after a report from a
'/>"/>
| Contact: Holly Korschun hkorsch@emory.edu 404-727-3990 Emory University Source:Eurekalert |